SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders watching guidance, subscriber engagement and advertising growth amid concerns about slowing growth, content quality and competition; recent leadership changes and layoffs add to the debate. Bulls see pessimism as overdone, while bears expect further weakness, leaving sentiment sharply divided ahead of the report.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp rebound on elevated volume has traders speculating about a news leak or buyout, partly reading CEO Angelos Stergious anniversary message as a signal; neither claim is confirmed. The main underlying focus is the Phase 3 REGAL trials final analysis, triggered at 80 deaths after 78 were last disclosed: bulls interpret the wait as a possible sign of longer survival, while skeptics note the results remain uncertain.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is largely tied to anticipation of the detailed Phase 3 melanoma cancer-vaccine results with Merck at ESMO, after positive topline results sparked a major revaluation. Traders are split between momentum-driven optimism about the broader oncology platform and concerns that expectations and valuation are stretched, with some anticipating a sell-the-news pullback.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp move is drawing attention as shares push above recent technical resistance, while traders point to anticipated DM1 and FSHD siRNA data as potential catalysts. Some see strength or possible short covering, while others caution that past rallies have faded and no new catalyst is confirmed in the discussion.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure amid broader concerns about neocloud funding, debt, and whether AI infrastructure spending will generate adequate returns; co-CEO Daniel Roberts comments that the data centers were cash-funded and customer prepayments help cover GPU costs are being cited as reassurance. Traders are split between viewing the selloff as an oversold buying opportunity and expecting further downside, with many frustrated that IREN has lagged peers.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.

Cardano

ADAs weak, range-bound trading and exposure to broader crypto-market selling dominate the discussion, with many traders frustrated by failed rallies and warning of more downside. Others view the pullback as consolidation and say they are accumulating or holding, while watching technical resistance and Bitcoins direction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM shares are under pressure after a quarterly earnings beat failed to offset a narrowed full-year profit outlook that left the midpoint unchanged; weaker U.S. sales and market share also weighed on the reaction. Traders are split between viewing the selloff as overdone given stronger cash-flow guidance and a new buyback, and focusing on the lack of a higher profit outlook.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs earnings beat and raised outlook have been met with a sharp selloff, prompting frustration and debate over why strong demand and guidance have not supported the shares. Traders point to profit-taking and elevated expectations, while cost pressures, weaker cash conversion and an insurance-unit loss have raised questions about margins and the quality of the results.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, driving attention alongside analyst upgrades. Traders are divided over the modest placebo-adjusted symptom improvement and concerns about discontinuations and agitation, with some viewing the data as a positive proof of concept and others arguing the rally may fade.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp has driven the sharp share move, with traders viewing the cash sale as a balance-sheet and strategic reset. The community is split between bullish momentum and concern that divesting a revenue-generating unit could leave the remaining business smaller and debt pressures unresolved.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals

Equity

Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule.


Biofrontera (BFRI) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates

Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of +70.59% and +33.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates

BioStem Technologies, Inc. (BSEM) delivered earnings and revenue surprises of -4.00% and +23.43%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates

Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +10.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +18.18% and -80.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of +26.32% and +16.42%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Biofrontera (BFRI) Q1 2026 Earnings Transcript

Transcript: Biofrontera Q1 2026 Earnings Conference Call

Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates

Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of -127.78% and +6.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company focuses on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.

Biofrontera Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Bristol Myers Squibb faces an FDA decision on Sept. 30 for expanding Camzyos to adolescents with obstructive hypertrophic cardiomyopathy.</li><li>Scholar Rock’s Isembyld and Biofrontera's (BFRI) Ameluz received FDA clearance ahead of their scheduled late-September PDUFA dates.</li><li>Mirum Pharmaceuticals’ Atebrioz got FDA approval on Friday for patients aged 12-18 with an ultra-rare genetic disease.</li></ul>Biotech and pharmaceutical investors have key U.S. Food and Drug Administration (FDA) events to watch this week, including decisions on treatments for a rare genetic disorder and a heart condition, while several other drugs originally scheduled for late-September decisions have already received regulatory clearance.Bristol Myers Squibb (<a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">BMY</a>) awaits an FDA decision on expanding Camzyos to adolescents with obstructive hypertrophic cardiomyopathy, a condition in which thickened heart muscle blocks blood flow. Stockholm-listed Egetis Therapeutics also faces a decision on Emcitate for MCT8 deficiency, a rare genetic disorder that affects how thyroid hormones reach the brain and other tissues.Meanwhile, Biofrontera (BFRI) and Scholar Rock (SRRK) entered the week with decisions originally scheduled for this period, while Mirum Pharmaceuticals (MIRM) and Incyte (INCY) received FDA approval for Atebrioz late last week.A PDUFA date is the target deadline by which the FDA aims to complete its review of a drug application.<img src="https://news.stocktwits-cdn.com/4_Hpst_fda_decisions_this_week_1_7833148823.png" alt="4Hpst-fda-decisions-this-week- (1).png"><h2 class="st-heading-2">Bristol Myers Awaits Camzyos Label Expansion</h2>The FDA is scheduled to make a decision on Bristol Myers Squibb (<a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">BMY</a>) on September 30. The regulatory body will decide whether to expand the use of Camzyos (Mavacamten) to adolescents ages 12 to under 18 with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).Obstructive HCM is a condition in which the heart muscle becomes abnormally thick, potentially blocking blood flow out of the heart. Patients can experience shortness of breath, fatigue and chest pain.Camzyos is already FDA-approved for certain adults with symptomatic oHCM. Bristol Myers said the safety profile among adolescents was similar to that previously observed in adults.If cleared, Camzyos would become the first cardiac myosin inhibitor approved in the U.S. for adolescents with oHCM, according to the company.<h2 class="st-heading-2">Egetis Awaits FDA Decision On Rare Genetic Disorder Drug</h2>Egetis Therapeutics faces a September 28 decision on Emcitate for MCT8 deficiency.If approved, Emcitate would become the first FDA-approved treatment for MCT8 deficiency in the U.S. The drug is already approved in the European Union, and the FDA has already granted the application Priority Review. Emcitate has also received Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations from the FDA.<h2 class="st-heading-2">FDA Already Acted On Several Late-September Decisions</h2>Several other drugs that had been heading toward FDA decisions around this week have already received regulatory clearance.Scholar Rock’s (SRRK) Isembyld was scheduled for a September 30 PDUFA date, but the FDA approved the treatment on Sept. 11 for adults and children aged two years and older with spinal muscular atrophy who are already receiving an SMN2-targeted treatment.Spinal muscular atrophy is a rare genetic disease that causes progressive muscle weakness and loss of motor function. Scholar Rock said Isembyld is the first and only muscle-targeted treatment approved for SMA. However, SRRK shares are down more than 12% since the approval.Biofrontera’s (BFRI) Ameluz also received an FDA decision ahead of its September 28 PDUFA date. The label expansion covers Ameluz photodynamic therapy for superficial basal cell carcinoma, a common form of skin cancer. BFRI shares have seen an even sharper decline, down 23% since the FDA decision on September 14.<h2 class="st-heading-2">Mirum Gets FOP Drug Approval</h2>On Friday, the FDA approved Mirum Pharmaceuticals’ (MIRM) Atebrioz for patients aged 12 and older with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disease that causes bone to form in muscles and other soft tissues, gradually restricting movement.Mirum expects Atebrioz to become available in the U.S. in October.The biotech firm acquired worldwide rights to Atebrioz from Incyte (INCY) earlier this year. Incyte remains eligible for milestone payments and royalties from the drug.MIRM shares closed Friday’s session 0.4% higher and are currently trading up 3% in pre-market.<h2 class="st-heading-2">How Have BFRI, <a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">BMY</a>, SRRK, MIRM And INCY Performed YTD?</h2><img src="https://news.stocktwits-cdn.com/Biotech_63ba5c5882.png" alt="Biotech.png">Among these stocks, Biofrontera (BFRI) has gained the most this year, rising nearly 63%, followed by Incyte (INCY) at more than 22% and Bristol Myers Squibb (<a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">BMY</a>) at about 18%. Scholar Rock (SRRK) and Mirum Pharmaceuticals (MIRM) have each gained roughly 13%.Also read:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/critical-minerals-wrap-crml-grml-surge-on-greenland-deal-us-stockpile-push-accelerates-as-trump-xi-talks-put-rare-earths-in-spotlight/cZMg2lHRBOY">Critical Minerals Wrap: CRML, GRML Surge On Greenland Deal, US Stockpile Push Accelerates As Trump-Xi Talks Put Rare Earths In Spotlight</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Biotech and pharmaceutical investors have key U.S. Food and Drug Administration (FDA) events to watch this week, including decisions on treatments for a rare genetic disorder and a heart condition, while several other drugs originally scheduled for late-S

FDA Decision Watch: BMY, EGTX Await Key Rulings As BFRI, SRRK, MIRM Win Early Approvals 

Bristol-Myers Squibb Co.

Incyte Corp.

Mirum Pharmaceuticals Inc

Scholar Rock Holding Corp

SPDR S&P Biotech ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$0.8104
Prev Close	$0.8057
Open	$0.8227
Dividend Yield	0.00%
50-Day Moving Average	$1.24
Beta	0.83
Avg. Volume	714,511.01
PE Ratio	-1.37

52-Week High	$1.66
52-Week Low	$0.5547
Market Capitalization	$11.97M
EPS (Annual)	-$1.04
Price to Book	1.92
Revenue Per Employee	$453,315.22

Feed

News

Sentiment

Earnings

Fundamentals

Info

BFRI Fundamentals